Group 1 - The core viewpoint of the article highlights that Brainstorm Aurora-B (06681) has deposited shares worth HKD 1.959 billion into Guotai Junan (Hong Kong), representing 20.77% of the total shareholding [1] - The company has recently signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1] - Additionally, the joint application for the "Precision Intelligent Diagnosis and Treatment Innovation and Transformation Key Laboratory for Mental Disorders" with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering has been officially approved for establishment [1]

Major Events - Brain动极光-B (06681) signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Mental Health Center [1] - Cohere New Energy (00182) successfully completed a secondary listing on the Singapore Stock Exchange [1] - Bole康视云-B (02592) submitted a clinical trial application for the new drug CBT-009 to the Drug Evaluation Center [1] - Yingtong Holdings (06883) established a partnership with the Italian high-end fragrance brand CULTI to strengthen its high-end fragrance distribution network in China [1] - Weimeng Group (02013) initiated a business cooperation with Taobao Flash Purchase [1] - Dali普控股 (01921) officially became a qualified supplier for Saudi Aramco [1] - Yiming Anke-B (01541) regained global rights for IMM2510 and IMM27M [1] - Yuexiu Property (00123) subsidiary Shanghai Yuheng won a land parcel in Shanghai's Pudong New District [1] Operating Performance - Jinxin Reproductive (01951) reported a further narrowing of the overall decline in IVF egg retrieval cycles to -1.4% for 2025 [1] - Poly Real Estate Group (00119) achieved a cumulative contract sales amount of approximately 50.2 billion yuan for 2025, a year-on-year decrease of 7.38% [1] - Yadea Holdings (01585) issued a profit warning, expecting annual net profit to be no less than 2.9 billion yuan [1] - Jindi Commercial Real Estate (00535) reported a cumulative contract sales total of approximately 10.696 billion yuan for 2025, a year-on-year decrease of 47.33% [1] - Greentown Management Holdings (09979) estimated the construction fee for newly developed projects in 2025 to be 9.35 billion yuan, a year-on-year increase of approximately 0.4% [1] - Sunac China (01918) achieved a cumulative contract sales amount of approximately 36.84 billion yuan for 2025, a year-on-year decrease of 21.85% [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 腦動極光醫療科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06681 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | | 增加 / 減少 (-) | | 0 | | | USD | | 0 | | 本月底結存 | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | 本月底法定/註冊股本總 ...

Core Viewpoint - The company has signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][4]. Group 1: Collaboration Details - The collaboration with Peking University Sixth Hospital includes the development of digital therapies and clinical application research, focusing on ADHD cognitive digital therapy effectiveness and a precision intelligent diagnosis system for depression [2]. - The research scope encompasses developing digital therapy products for emotional and behavioral issues across the entire lifecycle, including clinical validation of cognitive digital therapies aimed at improving learning abilities in children with ADHD [2]. - The partnership with Shandong Provincial Mental Health Center involves developing cognitive screening and intervention systems for mental disorders, as well as methods for capacity training guided by virtual humans [3]. Group 2: Laboratory Establishment - The "Precision Intelligent Diagnosis and Innovation Transformation Key Laboratory for Mental Diseases" has been officially approved, with the company as a core co-construction unit alongside Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering [3]. - The laboratory will focus on innovation and transformation driven by clinical needs in mental health, integrating clinical medicine, basic research, technology development, and hardware innovation [3]. Group 3: Strategic Positioning - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health facility, to promote the clinical application of digital mental health therapies [4]. - The recent collaborations expand the company's network across key mental health hospitals in China, creating a comprehensive commercial landing network from national flagship centers to regional hubs and specialized hospitals [4]. - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's pioneering advantage in the digital mental health therapy field, accelerating product development and commercialization [4].

Core Viewpoint - The company has signed significant business cooperation agreements with Beijing University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][4]. Group 1: Collaboration Details - The collaboration with Beijing University Sixth Hospital includes the development of digital therapies and clinical application research, focusing on attention deficit hyperactivity disorder (ADHD) cognitive digital therapy and a precision intelligent diagnosis system for depression [2]. - The research scope encompasses the development of digital therapy products for emotional and behavioral issues across the entire lifecycle, including clinical validation of cognitive digital therapies aimed at improving learning abilities in children with ADHD [2]. - The partnership with Shandong Provincial Mental Health Center involves the development of cognitive screening and intervention systems for mental disorders, as well as methods for capacity training guided by virtual humans [3]. Group 2: Laboratory Establishment - The "Precision Intelligent Diagnosis and Innovation Transformation Key Laboratory for Mental Diseases" has been officially approved, with the company as a core co-construction unit alongside Beijing University Sixth Hospital and the National Engineering Research Center for Software Engineering [3]. - The laboratory will focus on innovation and transformation driven by clinical needs in mental health, integrating clinical medicine, basic research, technology development, and hardware innovation [3]. Group 3: Strategic Positioning - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health facility, to promote the clinical application of digital mental health therapies [4]. - The recent collaborations further expand the company's network within core mental health specialty hospitals across the country, creating a comprehensive commercial landing network from national flagship centers to regional hubs and key specialty hospitals [4]. - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's first-mover advantage in the digital mental health therapy sector, accelerating product development and commercialization processes [4].

Core Viewpoint - The company has signed significant business cooperation agreements with Beijing University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][2][3]. Group 1: Joint Research Content - The research will focus on developing digital therapies and clinical applications, including the effectiveness of cognitive digital therapies for Attention Deficit Hyperactivity Disorder (ADHD) and a precision intelligent diagnosis system for depression [2]. - The research scope includes developing digital therapy products for emotional and behavioral issues across the entire lifecycle, with clinical validation for various age groups [2][3]. Group 2: Commercial Cooperation Content - The company will collaborate on digital technology services for cognitive disorder diagnosis and treatment, establishing a health management system covering elderly, children, and adults [2][3]. Group 3: Establishment of Key Laboratory - The "Beijing Key Laboratory for Precision Intelligent Diagnosis and Transformation of Mental Disorders" has been officially approved, with the company as a core co-builder [4]. - The laboratory will focus on innovation and transformation driven by clinical needs, integrating clinical medicine, basic research, technology development, and hardware innovation [4]. Group 4: Strategic Importance - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's pioneering advantage in the field of digital mental health therapies, accelerating product development and commercialization [5]. - The company aims to continue partnerships with top medical institutions to build a nationwide integrated digital mental health service system [5].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 及 獲批精神疾病精準智能診療創新轉化北京市重點實驗室 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發佈的公告，目的是使廣大投資者了解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣佈，本公司近期與北京大學第六醫院及山東省 精神衛生中心（統稱「合作方」）分別簽訂重要業務合作協議（統稱「業務合作協 議」），共同推進精神健康數字療法產品的研發與商業化。此外，本公司與北京大 學第六醫院、北京大學軟件工程國家工程研究中心聯合申報的「精神疾病精準智 能診療創新轉化北京市重點實驗室」（「實驗室」）已正式獲准組建。 一、與北京大學第六醫院簽訂業務合作協議 1. 聯合研發內容 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 簽訂重要業務合作協議 研究內 ...

Group 1 - The Hong Kong stock market's brain-computer interface sector experienced a decline, with MicroPort NeuroTech (02172.HK) dropping over 7% [1] - Nanjing Panda Electronics Co., Ltd. (00553.HK) and BrainCo Inc. (06681.HK) both fell nearly 6% [1] - Xinwei Medical-B (心玮医疗-B) saw a decline of nearly 3% [1]

Group 1: Neuralink and Brain-Computer Interface Stocks - Neuralink, founded by Elon Musk, plans to start large-scale production of brain-computer interface devices in 2026, leading to a significant surge in related stocks [1] - Nanjing Panda Electronics (00553) saw a rise of over 44%, while other companies like Xinwei Medical-B (06609), Micron Brain Science (02172), and Brainhole Laser-B (06681) increased by 11.90%, 17%, and 19.8% respectively [1] Group 2: Pharmaceutical Sector Performance - The pharmaceutical sector showed strong performance, with China's innovative drug licensing exceeding $100 billion last year [1] - Companies such as Gilead Sciences-B (01672), Cloudtop New Medicine (01952), and Innovent Biologics (01801) experienced stock increases of 8.85%, 5.65%, and 6.28% respectively [1] Group 3: Robotics and Technology Stocks - Woan Robotics (06600) saw its stock rise by over 27%, with a midday increase of 19.57% as it prepares to launch its first humanoid household robot [1] - The company reported a compound annual growth rate of 49% in revenue over the past three years [1] Group 4: Other Notable Stock Movements - Kuaishou-W (01024) increased by over 9%, with foreign investors optimistic about its revenue outlook for next year [1] - Fuhong Hanlin (02696) rose by 7% after three of its innovative cancer drugs received IND acceptance [1] - Kelun-Biotech (06990) gained over 7% following the approval of its clinical trial application for the new drug ITGB6 ADC SKB105 [2] - The Golden Group (03939) increased by 3.94% due to the successful implementation of key projects at the Solomon Gold Mine [3]

Core Viewpoint - Neuralink, founded by Elon Musk, is set to begin large-scale production of its brain-machine interface technology this year, marking a significant advancement in automated surgical procedures and bringing previously speculative technology into mass production [1][4]. Company Developments - Neuralink has announced that it will automate surgical processes, reducing the insertion time for its devices to 1.5 seconds and cutting manufacturing costs by 95% [4]. - As of September 2025, 12 patients with severe paralysis have successfully implanted Neuralink devices, enabling them to perform tasks such as gaming and social media interaction [5]. - The company raised $650 million (approximately 4.55 billion RMB) in a funding round completed in June [5]. Industry Trends - The brain-machine interface sector is experiencing a surge in interest and investment, with companies like阶梯医疗, 博睿康, and 芯智达 entering clinical validation stages [9]. - The Chinese government has included brain science and related research in its "14th Five-Year Plan," aiming for significant technological breakthroughs by 2027 [10]. - The market for brain-machine interfaces in China is projected to grow from 3.2 billion RMB in 2024 to over 5.5 billion RMB by 2027, with global market estimates reaching $40 billion by 2030 [11]. Market Response - Following Neuralink's announcement, stocks related to brain-machine interfaces surged, with notable increases in companies such as 南京熊猫电子股份 (up 43.69%) and 微创脑科学 (up 16.19%) [2][3]. - A-share market also saw significant gains, with multiple companies hitting the upper limit of their trading range [2]. Future Outlook - Neuralink's roadmap includes plans for motion decoding for patients with spinal injuries and visual encoding for those with vision impairments, potentially addressing mental health issues and enhancing cognitive abilities [6]. - The industry is expected to benefit from technological breakthroughs, policy support, and collaborative ecosystems, with a projected CAGR of 17% from 2025 to 2034 [11].